|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.88 HKD | +4.76% |
|
-6.53% | -8.69% |
| 03-04 | Abbisko Doses First Patient in Tumor Drug Trial | MT |
| 03-03 | Abbisko Cayman says CEO purchased total 45,000 shares of co at average price HK$11.26 per share | RE |
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
Profitability | ||||||
Return on Assets | -18.57 | -12.36 | -12.08 | -13.87 | -0.64 | |
Return on Total Capital | -19.76 | -12.79 | -12.48 | -14.49 | -0.67 | |
Return On Equity % | 90.36 | -252.96 | -20.3 | -19.95 | 1.44 | |
Return on Common Equity | 90.36 | -252.96 | -20.3 | -19.95 | 1.44 | |
Margin Analysis | ||||||
Gross Profit Margin % | 100 | 100 | - | 100 | 100 | |
SG&A Margin | 289.89 | 550.11 | - | 505.78 | 14.72 | |
EBITDA Margin % | -1.96K | -1.43K | - | -2.65K | -2.14 | |
EBITA Margin % | -2K | -1.44K | - | -2.68K | -4.28 | |
EBIT Margin % | -2.01K | -1.45K | - | -2.68K | -4.28 | |
Income From Continuing Operations Margin % | -9.68K | -7.98K | - | -2.26K | 5.62 | |
Net Income Margin % | -9.68K | -7.98K | - | -2.26K | 5.62 | |
Net Avail. For Common Margin % | -9.68K | -7.98K | - | -2.26K | 5.62 | |
Normalized Net Income Margin | -6.05K | -803.43 | - | -1.42K | 9.68 | |
Levered Free Cash Flow Margin | -1.05K | -201.23 | - | -1.41K | 14.61 | |
Unlevered Free Cash Flow Margin | -1.05K | -198.59 | - | -1.4K | 14.81 | |
Asset Turnover | ||||||
Asset Turnover | 0.01 | 0.01 | - | 0.01 | 0.24 | |
Fixed Assets Turnover | 0.42 | 0.54 | - | 0.26 | 8.25 | |
Short Term Liquidity | ||||||
Current Ratio | 20.47 | 35.1 | 22.39 | 18.7 | 14.92 | |
Quick Ratio | 20.05 | 34.98 | 22.19 | 18.42 | 14.82 | |
Operating Cash Flow to Current Liabilities | -3.7 | -2.31 | -3.2 | -4.07 | -0.1 | |
Long Term Solvency | ||||||
Total Debt/Equity | -156.01 | 2.12 | 1.94 | 1.8 | 1.24 | |
Total Debt / Total Capital | 278.53 | 2.08 | 1.91 | 1.77 | 1.22 | |
LT Debt/Equity | -155.62 | 1.77 | 1.52 | 1.27 | 0.68 | |
Long-Term Debt / Total Capital | 277.83 | 1.74 | 1.49 | 1.25 | 0.67 | |
Total Liabilities / Total Assets | 265.92 | 4.46 | 5.75 | 6.35 | 7.06 | |
EBIT / Interest Expense | -433.52 | -342.25 | -185.17 | -235.52 | -13.43 | |
EBITDA / Interest Expense | -405.44 | -329.86 | -179.91 | -228.25 | -0.72 | |
(EBITDA - Capex) / Interest Expense | -415.68 | -339.26 | -187.22 | -232.68 | -3.25 | |
Total Debt / EBITDA | -12.58 | -0.17 | -0.09 | -0.07 | -21.03 | |
Net Debt / EBITDA | -7.93 | 7.96 | 4.83 | 3.99 | 1.72K | |
Total Debt / (EBITDA - Capex) | -12.27 | -0.17 | -0.09 | -0.07 | -4.65 | |
Net Debt / (EBITDA - Capex) | -7.74 | 7.74 | 4.64 | 3.91 | 379.67 | |
Growth Over Prior Year | ||||||
Total Revenues, 1 Yr. Growth % | 90.3 | - | - | - | 2.54K | |
Gross Profit, 1 Yr. Growth % | 90.3 | - | - | - | 2.54K | |
EBITDA, 1 Yr. Growth % | 48.24 | 115.25 | 52.02 | 2.46 | -97.86 | |
EBITA, 1 Yr. Growth % | 47.11 | 113.1 | 51.48 | 2.79 | -95.77 | |
EBIT, 1 Yr. Growth % | 47.25 | 113.36 | 51.48 | 2.79 | -95.77 | |
Earnings From Cont. Operations, 1 Yr. Growth % | 427.69 | 156.14 | -72.62 | -12.92 | -106.56 | |
Net Income, 1 Yr. Growth % | 427.69 | 156.14 | -72.62 | -12.92 | -106.56 | |
Normalized Net Income, 1 Yr. Growth % | 427.69 | 112.49 | 73.49 | -12.78 | -118.05 | |
Diluted EPS Before Extra, 1 Yr. Growth % | - | 8.17 | -89.64 | -16.49 | -105.97 | |
Net Property, Plant and Equip., 1 Yr. Growth % | -26.33 | 368.99 | 11.55 | -10.29 | -23.83 | |
Total Assets, 1 Yr. Growth % | 107.96 | 298.6 | -6.22 | -15.03 | -0.39 | |
Tangible Book Value, 1 Yr. Growth % | 140.82 | -329.14 | -7.55 | -15.6 | -1.16 | |
Common Equity, 1 Yr. Growth % | 140.72 | -329.51 | -7.48 | -15.57 | -1.15 | |
Cash From Operations, 1 Yr. Growth % | 41.95 | 38.17 | 102.6 | 29.32 | -97.09 | |
Capital Expenditures, 1 Yr. Growth % | 0.79 | 160.37 | 117.64 | -51.05 | -57.63 | |
Levered Free Cash Flow, 1 Yr. Growth % | - | -43.83 | 329.41 | 36.67 | -126.75 | |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | -44.42 | 331.4 | 37.15 | -127.25 | |
Compound Annual Growth Rate Over Two Years | ||||||
Total Revenues, 2 Yr. CAGR % | - | 143.13 | - | -8.33 | - | |
Gross Profit, 2 Yr. CAGR % | - | 143.13 | - | -8.33 | - | |
EBITDA, 2 Yr. CAGR % | - | 83.14 | 81.09 | 24.81 | -85.2 | |
EBITA, 2 Yr. CAGR % | - | 81.42 | 79.86 | 24.78 | -79.16 | |
EBIT, 2 Yr. CAGR % | - | 81.61 | 79.78 | 24.78 | -79.16 | |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | 267.64 | -16.25 | -51.17 | -76.1 | |
Net Income, 2 Yr. CAGR % | - | 267.64 | -16.25 | -51.17 | -76.1 | |
Normalized Net Income, 2 Yr. CAGR % | - | 47.56 | 90.05 | 23.01 | -60.32 | |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | - | -66.52 | -70.58 | -77.62 | |
Net Property, Plant and Equip., 2 Yr. CAGR % | - | 85.88 | 128.73 | 0.04 | -17.34 | |
Total Assets, 2 Yr. CAGR % | - | 187.91 | 93.34 | -10.73 | -8 | |
Tangible Book Value, 2 Yr. CAGR % | - | 134.91 | 45.55 | -11.67 | -8.67 | |
Common Equity, 2 Yr. CAGR % | - | 135.05 | 45.72 | -11.62 | -8.64 | |
Cash From Operations, 2 Yr. CAGR % | - | 43.16 | 67.31 | 61.87 | -80.61 | |
Capital Expenditures, 2 Yr. CAGR % | - | 61.99 | 138.05 | 3.22 | -54.46 | |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | 55.31 | 142.26 | -38.71 | |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | 54.84 | 143.24 | -38.02 | |
Compound Annual Growth Rate Over Three Years | ||||||
Total Revenues, 3 Yr. CAGR % | - | - | - | - | 181.13 | |
Gross Profit, 3 Yr. CAGR % | - | - | - | - | 181.13 | |
EBITDA, 3 Yr. CAGR % | - | - | 72.24 | 49.78 | -67.83 | |
EBITA, 3 Yr. CAGR % | - | - | 70.96 | 49.26 | -59.63 | |
EBIT, 3 Yr. CAGR % | - | - | 70.96 | 49.22 | -59.63 | |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | 54.68 | -15.16 | -74.99 | |
Net Income, 3 Yr. CAGR % | - | - | 54.68 | -15.16 | -74.99 | |
Normalized Net Income, 3 Yr. CAGR % | - | - | 54.68 | 46.6 | -35.12 | |
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | - | -54.6 | -82.69 | |
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | 56.79 | 67.43 | -8.65 | |
Total Assets, 3 Yr. CAGR % | - | - | 98.1 | 47 | -7.41 | |
Tangible Book Value, 3 Yr. CAGR % | - | - | 72.15 | 21.37 | -8.3 | |
Common Equity, 3 Yr. CAGR % | - | - | 72.26 | 21.48 | -8.26 | |
Cash From Operations, 3 Yr. CAGR % | - | - | 60.73 | 53.55 | -57.62 | |
Capital Expenditures, 3 Yr. CAGR % | - | - | 78.75 | 40.51 | -23.29 | |
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | - | 48.83 | 17.28 | |
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | - | 48.71 | 18.33 | |
Compound Annual Growth Rate Over Five Years | ||||||
Total Revenues, 5 Yr. CAGR % | - | - | - | - | 165.27 | |
Gross Profit, 5 Yr. CAGR % | - | - | - | - | 165.27 | |
EBITDA, 5 Yr. CAGR % | - | - | - | - | -35.47 | |
EBITA, 5 Yr. CAGR % | - | - | - | - | -26.33 | |
EBIT, 5 Yr. CAGR % | - | - | - | - | -26.33 | |
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | - | - | -26.72 | |
Net Income, 5 Yr. CAGR % | - | - | - | - | -26.72 | |
Normalized Net Income, 5 Yr. CAGR % | - | - | - | - | -10.24 | |
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | - | - | 21.37 | |
Total Assets, 5 Yr. CAGR % | - | - | - | - | 45.76 | |
Tangible Book Value, 5 Yr. CAGR % | - | - | - | - | 33.6 | |
Common Equity, 5 Yr. CAGR % | - | - | - | - | 33.66 | |
Cash From Operations, 5 Yr. CAGR % | - | - | - | - | -31.03 | |
Capital Expenditures, 5 Yr. CAGR % | - | - | - | - | 3.45 |
- Stock Market
- Equities
- 2256 Stock
- Financials Abbisko Cayman Limited
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















